Romosozumab

Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a BMD T-score of at least –2.8 at the total hip or –3.1 at the lumbar spine at baseline, according to study findings.

SAN DIEGO — Romosozumab is superior to denosumab for increasing bone mineral density in the spine at 12 months among chronic glucocorticoid users with osteoporosis at high fracture risk, according to data presented at ACR Convergence 2023.

During the past 20 years, Endocrine Today has covered the latest advancements surrounding osteoporosis care. For its 20th year, the publication is taking a look back.

Denosumab is associated with a greater increase in lumbar spine bone mineral density at 12 months compared with ibandronate as a sequential treatment after 12 months of romosozumab therapy, according to study findings published in Bone.

Romosozumab improved bone mineral density at the lumbar spine, total hip and femoral neck, and reduced the relative risk for fractures in women with osteoporosis and mild-to-moderate chronic kidney disease, according to study data.

Postmenopausal women experienced more widespread vertebral bone accrual at the lumbar spine at 12 months of romosozumab treatment compared with teriparatide, according to study data published in the Journal of Bone and Mineral Research.

Romosozumab is associated with marked reductions in all vertebral fracture grades, and these are sustained after transition to antiresorptive agents, post hoc analyses from the FRAME and ARCH studies show.

Data showed that 1 year of romosozumab followed by a year of alendronate was associated with larger gains in bone mineral density at the lumbar spine than 2 years of alendronate alone in postmenopausal women with osteoporosis.

Postmenopausal women with osteoporosis receiving romosozumab for 12 months had larger improvements in bone mineral density and bone strength at the lumbar spine compared with those receiving alendronate alone, according to study data.

Osteoporosis, long considered a disease of older age, is estimated to affect about 25% of women aged at least 65 years, according to the CDC.